Skip to main content

Day: August 18, 2021

Sonasoft and Information Visibility Technology (IVT) Sign Multiyear Partnership to Transform Healthcare

San Jose, CA, Aug. 18, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Sonasoft Corp. (OTCQB: SSFT) has executed a strategic partnership with Information Visibility Technology (IVT), a pioneer in healthcare information technologies. IVT will be leveraging Sonasoft’s AI engine, SAIBRE, to uncover key business insights and intelligence. “This is a great fit for our new SAIBRE AI engine,” says Mike Khanna, Sonasoft’s CEO. “IVT’s expert domain knowledge combined with SAIBRE brings a new approach, allowing us to rapidly prototype and deploy cost saving solutions to the healthcare space.” IVT and Sonasoft will initially collaborate on deploying two AI bots to reduce the inflexibility often found in healthcare solutions. These include an inventory management bot for supply and demand forecasting and a dynamic pricing bot to move away...

Continue reading

Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom’s Macroglobulinemia

FLORHAM PARK, N.J., Aug. 18, 2021 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced it has been awarded a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 Million from the National Cancer Institute (NCI). The company is currently conducting a global pivotal study of iopofosine I-131 (also known as CLR 131) in Waldenstrom’s macroglobulinemia (WM) patients who have received at least two prior lines of therapy, including Bruton tyrosine kinase inhibitor failed or suboptimal response patients. The study was initiated in January of 2021 and is expected to take approximately 18 months to fully enroll. “We...

Continue reading

Unrivaled Expands Offering Through Exclusive Distribution Agreement with G-Eazy’s FlowerShop* Lifestyle and Wellness Brand

SANTA ANA, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) — Unrivaled Brands, Inc. (OTCQX:UNRV) (“Unrivaled” or the “Company”) announced that it has entered into an exclusive agreement with Feel Better LLC (Feel Better) and their licensing and production partner Halo Collective Inc (Halo). As part of the agreement, Unrivaled will be the exclusive distributor of Feel Better’s FlowerShop* branded products, a cannabis lifestyle and wellness brand, in more than 400 retail stores across California. Founded by Isaac Muwaswes, Gabriel Garcia, and G-Eazy, FlowerShop* complements Unrivaled’s existing distribution lineup of Korova, Sticks, Habit Labs, Cabana, and Serra products by offering a uniquely packaged lifestyle brand with an extensive marketing presence in California. The product lineup includes the FlowerShop* BUDVASE...

Continue reading

Healthy Consumer Credit Market Drives Return to Lending

Q2 2021 TransUnion Industry Insights Report explores credit trendsCII Levels Through the Past DecadeCredit Industry IndicatorCHICAGO, Aug. 18, 2021 (GLOBE NEWSWIRE) — The financial services industry is rebounding strongly from the early impacts of the COVID-19 pandemic, according to TransUnion’s (NYSE: TRU) Q2 2021 Quarterly Credit Industry Insights Report (CIIR). The auto, credit card, mortgage and personal loan industries exhibited renewed signs of strength at the mid-point of 2021. In the initial months of the pandemic, many lenders struggled with making credit available to consumers in the face of branch closures and a remote workforce. One year later, lenders have adapted and shifted to a digital-first origination strategy and enhanced their capabilities to originate new accounts virtually. Signs of this...

Continue reading

Beroni Initiates Manufacture of its Novel, Potential Anti-Cancer Drug PENAO

NEW YORK and SYDNEY, Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) — Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based diversified biopharmaceutical enterprise, announced that PENAO Pty Ltd, its majority-owned, Sydney-based anti-cancer drug development company, has signed a drug manufacture contract with Aurigene Pharmaceutical Services, India, a subsidiary of Dr Reddy’s Laboratories Limited (NYSE: RDY; BSE: 500124). This next-generation adenine nucleotide translocase (ANT) inhibitor, PENAO, was shown to be safe and well-tolerated in a phase I clinical trial conducted in Australia where encouraging efficacy data was observed. In a second clinical trial to commence H1 2022, PENAO is planned to be administered as twice-weekly injections to patients with advanced solid tumors. It is going to be a dose-finding study...

Continue reading

Codiak BioSciences Appoints Lini Pandite, MBChB, MBA to Board of Directors

CAMBRIDGE, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) — Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today it has appointed Lini Pandite, MBChB, MBA to its board of directors. As a board-certified oncologist and current Chief Medical Officer at Shattuck Labs, Dr. Pandite brings extensive expertise in oncology drug development and clinical application, diversifying the breadth of expertise represented on the board. “Lini’s experience will be highly relevant and complementary on our board, as she has led development of numerous novel oncology medicines over the course of her industry career and treated patients for more than a decade,” said Douglas E. Williams, Ph.D., President and Chief Executive...

Continue reading

DLH Awarded Contract for CDC NCHHSTP DHP Data Management Services

ATLANTA, Aug. 18, 2021 (GLOBE NEWSWIRE) — DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of innovative healthcare research, services, and solutions to federal agencies, today announced that it has been awarded a contract by the Centers for Disease Control and Prevention’s (“CDC”) Division of HIV Prevention (“DHP”) Data Management Services through data management and analysis, health informatics, and research support. The contract includes a base period of one year, with four one-year options, for a total value of $35 million. “We are thrilled to partner with DHP in support of their vision of a ‘future free of HIV,’” said Jeanine Christian, President of DLH’s Public Health & Scientific Research operating unit. “This contract extends DLH’s legacy in HIV research across the globe. We are proud...

Continue reading

Trading in FLSmidth & Co. A/S by Board member

Company announcement 10-2021, 18 August 2021 Tom Knutzen, Vice Chairman of the Board, has purchased 5,000 shares and consequently has a total shareholding of 25,000 shares.Contacts Media RelationsRasmus Windfeld, +45 40 44 60 60, rwin@flsmidth.com Investor RelationsNicolai Mauritzen, +45 30 93 18 51, nicm@flsmidth.comFLSmidth provides sustainable productivity to the global mining and cement industries. We deliver market-leading engineering, equipment and service solutions that enable our customers to improve performance, drive down costs and reduce environmental impact. Our operations span the globe and our close to 12,000 employees are present in more than 60 countries. In 2019, FLSmidth generated revenue of DKK 20.6 billion. www.flsmidth.comAttachmentCompany announcement 10 2021 Insider Trading

Continue reading

Progressive Reports July 2021 Results

MAYFIELD VILLAGE, OHIO, Aug. 18, 2021 (GLOBE NEWSWIRE) — The Progressive Corporation (NYSE:PGR) today reported the following results for July 2021:  July(millions, except per share amounts and ratios; unaudited)2021   2020   Change         Net premiums written $ 4,551.6     $ 4,109.3     11   %Net premiums earned $ 4,313.5     $ 3,781.4     14   %Net income $ 255.4     $ 812.0     (69 ) %Per share available to common shareholders $ 0.43     $ 1.38     (69 ) %Total pretax net realized gains (losses) on securities $ 122.7     $ 333.4     (63 ) %Combined ratio 96.7       83.5     13.2 pts.Average diluted equivalent common shares   587.2       587.8     0   %  July(thousands; unaudited)2021   2020   ChangePolicies in Force          Personal Lines          Agency – auto 8,014.2   7,435.4   8 %Direct...

Continue reading

Triterras Bolsters Structured Finance Team with Key Appointments

Frank Barbarino, CAIA, will lead fund origination and structuring; Amoy Chambers joins as head of legal for structuring and distribution SINGAPORE, Aug. 18, 2021 (GLOBE NEWSWIRE) — Triterras Inc. (Nasdaq: TRIT, TRITW) (“Triterras” or the “Company”), a leading fintech company focused on trade and trade finance, today announced appointing two management executives, as the company continues to accelerate the global availability of Kratos, its digital trade and trade finance platform, to lenders and capital providers worldwide. Frank Barbarino has joined Triterras as Americas Head, Funds Origination & Structuring. He will work closely with Triterras’ clients—institutional investors, including investment managers and asset owners— in structuring deals and deploying capital to trade finance. With more than two decades of experience...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.